Literature DB >> 6818733

Determination of unbound valproic acid concentration in plasma by equilibrium dialysis and gas--liquid chromatography: methodological aspects and observations in epileptic patients.

R Riva, F Albani, A Baruzzi, I Galvani, E Perucca.   

Abstract

An equilibrium dialysis technique for the separation of the free (unbound) concentration of valproic acid (VPA) in plasma is described together with a sensitive gas chromatographic assay for the quantitative determination of the drug in the dialysate. The overall coefficient of variation of the method was below 10%. By using a high permeability membrane, equilibration of the drug between the plasma and the buffer compartments was obtained after about 45 min at 37 degrees C. With this dialysis time, dilutional changes in the plasma compartment were negligible and there was no significant change in the plasma-free fatty acid (FFA) concentration. No passage of protein into the buffer solution was detected. When dialysis was prolonged for up to 4 h, a significant elevation in plasma FFA (with a corresponding rise in free VPA fraction) was observed. Storage of plasma samples at temperatures ranging from 4 to 37 degrees C for 8 h or longer before dialysis also resulted in an increased value of free VPA fraction and FFA concentration. The two effects were significantly correlated. The free fraction of VPA was found to increase with increasing total plasma concentration. This effect was observed both in vitro and in vivo in the plasma of 91 patients receiving chronic VPA therapy. The methodological problems of using equilibrium dialysis techniques for determining the free fraction of VPA are highlighted.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6818733     DOI: 10.1097/00007691-198212000-00003

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  12 in total

Review 1.  Therapeutic drug monitoring in pregnancy: rationale and current status.

Authors:  C Knott; F Reynolds
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

Review 2.  Measurement and analysis of unbound drug concentrations.

Authors:  J D Wright; F D Boudinot; M R Ujhelyi
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

3.  Nonlinear binding of valproic acid (VPA) and E-delta 2-valproic acid to rat plasma proteins.

Authors:  R L Semmes; D D Shen
Journal:  Pharm Res       Date:  1990-05       Impact factor: 4.200

4.  Free level monitoring of antiepileptic drugs. Clinical usefulness and case studies.

Authors:  E Perucca
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

5.  Differential transplacental binding of valproic acid: influence of free fatty acids.

Authors:  F Albani; R Riva; M Contin; A Baruzzi; M Altomare; G P Merlini; E Perucca
Journal:  Br J Clin Pharmacol       Date:  1984-06       Impact factor: 4.335

6.  Pharmacokinetics of prednisone and its metabolite prednisolone in children with nephrotic syndrome during the active phase and in remission.

Authors:  G Gatti; E Perucca; G M Frigo; L D Notarangelo; L Barberis; A Martini
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

Review 7.  Free drug concentration monitoring in clinical practice. Rationale and current status.

Authors:  C K Svensson; M N Woodruff; J G Baxter; D Lalka
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

8.  Distribution of sodium valproate in normal whole blood and in blood from patients with renal or hepatic disease.

Authors:  R J Shirkey; L B Jellett; D C Kappatos; T J Maling; A Macdonald
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

9.  Pharmacokinetics of free and total sodium valproate in adolescents and young adults during maintenance therapy.

Authors:  L Herngren; A Nergårdh
Journal:  J Neurol       Date:  1988-11       Impact factor: 4.849

Review 10.  Clinical pharmacokinetics of valproic acid--1988.

Authors:  G Zaccara; A Messori; F Moroni
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.